Average weight loss on Mounjaro in the first month: what the evidence actually shows

The myth: the first month predicts your total result

A question our prescribers hear most weeks is some version of: "I've only lost 2 kg in four weeks, is it working?" The short answer is almost certainly yes, and here is why the framing is worth adjusting.

The 2.5 mg starting dose is calibrated to minimise nausea and gut discomfort, not to maximise weight loss. Tirzepatide's appetite-suppressing and gastric-slowing effects are dose-dependent: they strengthen as the dose increases through the titration schedule. Expecting first-month results to match what the clinical trials showed at 15 mg (after 72 weeks of progressive titration) is like judging a long journey by the first few roundabouts.

What does move in month one? Appetite tends to fall noticeably for most people, sometimes within days of the first injection. Early weight change is also partly water, reduced bloating and a smaller food intake, all of which are real but different from the sustained reduction of body fat that accumulates over months. The longer-term average weight loss on Mounjaro paints a fuller picture of what the treatment can do when given enough time.

What the trial data says about early and average first-week loss

The SURMOUNT-1 trial, published in the New England Journal of Medicine, did not report a standalone four-week figure, because the study was designed around longer endpoints. What it did show is a consistent, progressive loss curve: participants lost weight at every stage of titration, with the rate accelerating as doses increased.

Average weight loss in the first week on Mounjaro is similarly difficult to pin to a precise number from trial data, early-week figures were not the primary focus. What is clear is that movement on the scale can be detectable within the first two weeks for some people, while others notice very little until their dose goes up. If you want the sharpest read on what week-by-week progress tends to look like, the week-one data page covers that in detail.

The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, confirms that Mounjaro is used alongside a reduced-calorie diet and increased physical activity, both of which independently shape first-month results. Someone who changes their eating habits on day one will likely see more early movement than someone who does not.

The factors that actually drive first-month results

Starting weight has a large effect. A person starting at 130 kg may see 4–6 kg move in the first month simply because a high absolute weight responds more dramatically to even modest calorie reduction. Someone at 90 kg with the same percentage loss would see a smaller number.

GI side effects also matter. Nausea, reduced appetite and occasional vomiting in the early weeks mean some people eat significantly less, which accelerates early loss. Others tolerate the starting dose well and see less dramatic early movement, neither pattern predicts long-run outcome. You can read more about how long Mounjaro takes to work in the context of the full titration timeline.

Mounjaro's results across the titration schedule (not just in month one) are covered in detail on the average weekly loss page. If you are comparing tirzepatide's profile with other medicines, the tirzepatide results overview draws on SURMOUNT-1 and SURMOUNT-5 data side by side.

What a realistic first month looks like in practice

Most people who start Mounjaro see some scale movement in the first four weeks, typically in the 1–5 kg range, with a wide spread either side of that. A smaller number see very little change and feel discouraged. A smaller number still see more. None of these outcomes mean the treatment is or is not working in a meaningful clinical sense, the prescriber picture is built over months, not weeks.

The first-month Mounjaro loss page goes into more depth on the clinical context for early progress. And if you have been reading about people's experiences on Mounjaro before and after accounts, it is worth noting that those accounts naturally over-represent dramatic outcomes.

For context on what Mounjaro costs through a private regulated pharmacy, and what that price includes, the Mounjaro cost breakdown is worth reading before you start comparing providers. The medicine itself is a prescription-only treatment; the consultation, the prescriber's clinical review and the supply chain you access are as much a part of the decision as the price.

If you are considering starting treatment, check your eligibility with our prescribers. Every application is reviewed the same day by a named, GPhC-registered Independent Prescriber, your consultation goes to a clinician, not a decision engine.